Premium
Low‐dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain‐Barré syndrome
Author(s) -
Go T
Publication year - 2001
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2001.tb03256.x
Subject(s) - hypercalcaemia , medicine , alkaline phosphatase , endocrinology , adverse effect , calcium , gastroenterology , biochemistry , enzyme , chemistry
A low dose of oral etidronate (3.7 mg kg −1 d −1 ) was administered for immobilization hypercalcaemia associated with Guillain‐Barré syndrome in a 12‐y‐old boy. There was a slight increase in osteoblastic bone formation reflected by alkaline phosphatase and in particular bone‐specific alkaline phosphatase during the treatment and serum calcium decreased to the normal range within 2 wk. No adverse side effects were observed and the patient's linear growth subsequently progressed. Conclusion : A low dose of oral etidronate is safe and effective for treatment of immobilization hypercalcaemia in children, without inhibiting bone formation.